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Abstract: Epstein-Barr virus (EBV) is a ubiquitous B-cell trophic herpesvirus associated with a variety of histologically 
diverse B-cell lymphomas, each associated with specific viral-latency gene expression programs. Initial infection 
drives resting B-cells to differentiate via an atypical germinal centre reaction into memory B-cells, where the virus 
resides in a latent state. The mechanisms that underpin this process have yet to be fully elucidated. EBV expresses 
more than 40 microRNAs (miRNAs). The alternatively spliced BamHI A rightward transcripts (BARTs) are the tem-
plate for two large miRNA clusters (BARTs A and B), that comprise the majority of all known EBV-miRNAs. Although 
BART-miRNAs are abundantly expressed in all latency programs, few BART-miRNA targets have been identified and 
their function is poorly understood. The early B-cell factor 1 (EBF1) was identified using bioinformaticss analysis 
as a novel target of EBV-miRNA BART11-5p, encoded by BART cluster B. EBF1 is an important B-cell transcription 
factor that regulates many B-cell specific genes including Pax5, BCR and CD40 and is critical for germinal centre 
formation. Using luciferase reporter assays and a series of BART-constructs, we confirmed silencing via the EBF1 
3’ untranslated region (UTR) and identified the target site as 2137-2159 bp after the stop codon. Results were 
confirmed following transfection of a BART11-5p mimic, which was able to silence via the predicted target site. Our 
findings highlight a potential role of BART-miRNAs in the regulation of B-cell differentiation.
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Introduction
The B-cell lymphotrophic gamma-herpesvirus 
Epstein-Barr virus (EBV) infects over 90% of the 
population [1]. Following primary infection, the 
virus establishes latency within host B-cells [2]. 
Through a series of viral gene expression pro-
grams, known as latency programs, the virus 
evades immune surveillance and drives infect-
ed cells through a B-cell terminal differentia-
tion process, the mechanisms of which have 
yet to be fully elucidated [3]. This gives the virus 
access to the long lived memory B-cell com-
partment allowing persistence for the life of the 
host. Although infection is typically benign, EBV 
is strongly implicated in a range of histologically 
diverse B-cell lymphomas including Burkitt lym-
phoma (BL), Hodgkin lymphoma (HL), diffuse 
large B-cell lymphoma (DLBCL) and post-trans-
plant lymphoproliferative disease (PTLD) [4-8], 
the morphologies of which are identical to their 
EBV-negative malignant counterparts. Each is 
associated with distinct latency expression pro-
files [3, 9]. 
miRNAs are small RNA molecules (usually 
20-22 nucleotides in length) that attenuate 
gene expression at a post-transcriptional level 
[10, 11]. They are important developmental 
regulators and have been associated in the 
development of many cancers. A number of 
viruses have now been identified that encode 
miRNAs, the first of which was EBV [12]. 
Currently, more than 40 miRNAs have been 
identified within the EBV genome [13-15]. EBV 
encodes these miRNAs within two genomic 
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regions, termed BamHI-M rightward open read-
ing frame 1 (BHRF1) and BamHI A rightward 
transcripts (BART). The miRNAs are found in 
the intronic regions with three miRNAs identi-
fied within the BHRF1 region and two large clus-
ters found in the BART region (BART-A and 
BART-B, as outlined in Figure 1A), expressing 
many alternatively spliced transcripts and of 
unknown coding content.
EBV is also known to deregulate several host 
miRNAs, which may contribute to its oncogenic 
potential [16-20]. Furthermore, the expression 
of EBV-miRNAs has been demonstrated in sev-
eral lymphoma types although their contribu-
tion to lymphomagenesis is not known [21, 22]. 
The expression of BHRF1 miRNAs is restricted 
to latency III expressing lymphomas such as 
PTLD whereas the expression of BART miRNAs 
has been detected in all tumor and latency 
types [12, 13, 21]. The expression of BART miR-
NAs can vary widely between tumor types [23]. 
Further, the expression of several EBV-miRNAs 
has been demonstrated to be deregulated with-
in lymphoma and that tumor type can be distin-
guished by profiling of EBV-miRNAs [24]. This 
suggests that EBV-miRNAs are indeed involved 
in the pathogenesis of lymphoma and may 
prove to be useful biomarkers for disease sta-
tus or therapeutic targets.
Although studies have determined EBV-miRNAs 
play a role primarily in protecting infected cells 
from apoptosis and immune evasion [25], rela-
tively few targets of EBV-miRNAs within the 
human genome have been identified and fully 
verified [22, 26-29]. As such their role in EBV 
pathogenesis and B-cell lymphomagenesis is 
not well understood. Using a combination of 
bioinformaticss analysis, luciferase reporter 
assays and a series of BART-constructs, we 
identify early B-cell factor 1 (EBF1), an impor-
tant B-cell transcription factor that is critical for 
germinal centre formation, as a novel target of 
EBV-miRNA BART11-5p. 
Methods
Bioinformaticss
An in silico analysis was performed to predict 
potential targets of EBV-miRNAs within the 
Figure 1. A: Location of the BART miRNAs within the EBV genome. Coding regions are indicated by shaded boxes 
with names above. Positions of miRNAs are indicated by vertical bars. Arrows represent promoters P1 and P2. Re-
gions used for EBV-miRNA expression constructs are indicated by horizontal bars above. B: Location the restricted 
EBV-miRNA expression constructs. The entire region shown is expressed by the EBV-miRNA expression construct 
pBART-B and identifies the miRNAs expressed by each EBV-miRNA expression construct. 
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human genome. A libra-
ry of human 3’ untrans-
lated region (UTR) sequ- 
ences was compiled fr- 
om the NCBI Reference 
Sequence (RefSeq) da-
tabase using the UCSC 
Table Browser (http://
genome.ucsc.edu/cgi-
bin/hgTables?org=hu-
man) and scanned us-
ing the miRanda v1.0b 
software package, us-
ing a minimum score 
threshold of 130 and a 
minimum energy of -16 
kcal/mol. The level of 
false positive results 
was estimated by first 
analysing the GC con-
tent distribution of the 
3’UTR library using the 
CodonW package (http: 
//codonw.sourceforge.
net/) and then generat-
ing 1000 1 kb random 
sequences using the 
Fabox online toolbox 
(ht tp://www.birc.au.
dk/~biopv/php/fabox/
random_ sequence_
generator.php) exhibit-
ing the same GC distri-
bution The random libr- 
ary was scanned with 
miRanda using the sa- 
me thresholds and cut 
off vlaues determined 
based on false-posi-
tives observed in the 
random data set. The 
targets exceeding the-
se cut off values were 
then scanned using a 
second miRNA predic-
tion algorithm, Target-
Scan 4.1 and targets 
predicted by both algo-
rithms were ranked. 
Preparation of EBV-
miRNA expression and 
luciferase reporter 
constructs
EBV-miRNA expression 
constructs were devel-
Table 1. Primer sequences
Primer Primer Sequence (5’-3’)
A. EBV miRNA expression constructs
BART-A-Eco-F1 ATATGAATTCACTGATAAGGACCGCGGAGT
BART-A-Eco-R1 TTAAGAATTCCTCCAGAGGGCAGACGTTAG
BART-B-Eco-F1 TAATGAATTCTCCCAAATGTCACCACAGAA
BART-B-Eco-R1 ATATGAATTCTCCAACAACCCCATAACGAT
B. Luciferase-3’UTR Expression Constructs
LMP1-Xba1-F1 ATAATCTAGACCTTTCTTTACTTCTAGGCATTACCA
LMP1-Xba1-R1 AATTTCTAGACTGTACTTTTATTTATTGCATCACAAG
LY75XbaF1 TAATTCTAGACCCTGCTAAATGCCATGTTT
LY75XbaR1 ATATTCTAGACAGCTGTGCTTTTCACATCAA
CTDSP2XbaF1 TAATTCTAGACAGTAGGGGACTTTCCCACA
CTDSP2XbaR1 ATATTCTAGACAGTCACAGTGGGAAGCAGA
MLLXbaF1 TAATTCTAGATGTTTGTGCCCTGTTGACAT
MLLXbaR1 ATATTCTAGATGACCCATCACAATTCCTCA
BCL2L11XbaF1 TAATTCTAGAAAACCAACAAGACCCAGCAC
BCL2L11XbaR1 ATATTCTAGAGTAAGCCAGGGAAACTGCAA
HIF1ANheF1 TAATGGCTAGCGGCACTCCACTCCTATTTGG
HIF1ANheR1 ATATGCTAGCCCAGATTTTGAAGGGTGGAA
BCL11ASpeF1 TAATACTAGTGGTTTGACAGAGGGGAACAG
BCL11ASpeR1 ATATACTAGTAAAGGGACAAAATGGGTGTATG
EBFSpeF1 TAATACTAGTAACAAAATCACCGACCTTGC
EBFSpeR1 ATATACTAGTAGGGCAATGTTATGCAATCC
CD59NheF1 TAATGGCTAGCCTGCGTAGTCCGCTTTCTCT
CD59NheR1 ATATGCTAGCAGTTAGCAGGAGGCTGGATG
CD59NheF2 TAATGGCTAGCGCACAAACAACCTCCTGTCA
CD59NheR2 ATATGCTAGCTTTTTCCCCCTTACTCCAAGA
HLADOASpeF1 TAATACTAGTAAATGACTTGTGGGAGACACC
HLADOASpeR1 ATATACTAGTGAAACACCTTTCCAATGATGC
CD207XbaF1 TAATTCTAGATGCTTCAAAATTGTCCCACA
CD207XbaR1 ATATTCTAGATGACCCAGGCAGCATTTTAT
C. Real time primers
RTQ-primer CGAATTCTAGAGCTCGAGGCAGGCGACATGGCTGGCTAGTTAAGCTTG-
GTACCGAGCTCGGATCCACTAGTCCTTTTTTTTTTTTTTTTTTTTTTTTT
miR-RTQ-Probe AGTGGATCCGAGCTCGGTACCAAGC
RTQ-uniR2 CGAATTCTAGAGCTCGAGGCA
U6 CAAATTCGTGAAGCGTTCCATA
miR-BART1-5p TCTTAGTGGAAGTGACGTGCTGT
miR-BART1-3p TAGCACCGCTATCCACTATGTCT
miR-BART4 GACCTGATGCTGCTGGTGTGCT
miR-BART5 CAAGGTGAATATAGCTGCCCATCG
miR-BART6-5p GGTTGGTCCAATCCATAGGCTTAAAA
miR-BART6-3p CGGGGATCGGACTAGCCTTAGA
miR-BART8* GTCACAATCTATGGGGTCGTAGAAAAA
miR-BART11-5p GACAGTTTGGTGCGCTAGTTGT
miR-BART11-3p ACGCACACCAGGCTGACTGCC
miR-BART14 TAAATGCTGCAGTAGTAGGGATAAAAAA
miR-BART15 AGTGGTTTTGTTTCCTTGATAGAAAAAA
miR-BART20-3p CATGAAGGCACAGCCTGTTACC
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oped by high fidelity PCR amplification of the 
two primary BART miRNA clusters using tem-
plate gDNA isolated from an established EBV-
transformed lymphoblastoid cell line (LCL) 
infected with the QIMR-WIL EBV strain, using 
primers listed in Table 1A. Of note, the com-
mon laboratory strain B95-8 was not used as it 
includes a deletion in the BART region, remov-
ing most of the BART miRNAs. PCR was per-
formed with the following PCR reaction, 1x HF 
Buffer, 0.2 µM of forward and reverse primers, 
0.2 mM dNTPs, 1 U Phusion Hot Start High-
fidelity DNA polymerase (Finnzymes) and 30 ng 
of template DNA. The following PCR program 
was used: 98°C for 30 seconds, 35 cycles of 
amplification (98°C for 5 seconds, 64°C for 15 
seconds and 72°C for 1 minute/kb) and 72°C 
for 5 minutes. Amplicons were cloned down-
stream of the CMV promoter of the pcDNA3.1 
vector (Invitrogen) using EcoRI restriction sites 
at the 5’ end of the miRNA sequences. The 
resulting two miRNA expression constructs 
were termed pBART-A, which encodes a cluster 
of BART miRNAs not including BART11-5p, and 
pBART-B which encodes BART11-5p (Figure 
1A). Constructs expressing restricted subsets 
of BART miRNAs were developed from pBART-
B, by the removal of miRNA sequences by 
digesting pBART-B with XhoI or HindIII, followed 
by re-ligation of the construct backbone, gener-
ating pBART-B1 and pBART-B3. A final EBV-
miRNA expression construct was developed by 
the digestion and subsequent re-ligation of 
pBART-B3 with NheI, generating pBART-B3* 
(Figure 1B). All constructs were verified by 
sequencing.
Luciferase reporter plasmids were constructed 
by cloning 3’UTR sequences of predicted target 
genes downstream of the luciferase ORF of the 
pGL3-Control vector (Promega). Primers were 
designed to encompass the miRNA target sites 
identified by the bioinformatics analysis (Table 
1B). Either Xba I, Nhe I or Spe I sites were added 
to the 5’ ends of primers dependent on the 
presence of restriction sites within the region to 
be amplified, enabling cloning into the Xba I site 
of the pGL3-Control vector. High fidelity PCR 
products were amplified as described above 
using template human gDNA (Roche) and con-
structs were verified by sequencing.
Transfections
HEK 293T cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Gibco) and 
10% foetal calf serum (FCS) and incubated at 
37°C, 6.5% CO2. Cells were passaged every two 
to three days. Cells were seeded at 80,000 
cells/well in 24 well plates 24 hours prior to 
transfection. 
When using EBV-miRNA expression constructs, 
cells were transfected using Lipofectamine LTX 
(Invitrogen). 500 ng total plasmid DNA was 
Table 2. EBV miRNA targets
A. Potential targets of EBV-encoded miRNAs
Accession # Target Gene miRanda score miRanda energy RNA hybrid EBV miRNA EBV-miR expressor
NM_002349 LY75 146 -29.34 -32.0 BART1-5p BART-A
NM_024007 EBF1 145 -30.12 -33.1 BART11-5p BART-B
NM_005730 CTDSP2 144 -32.75 -37.3 BART4 BART-A
NM_006538 BCL2-L11 143 -30.62 -35.7 BART4 BART-A
NM_203331 CD59 141
139
-23.25,
-30.36
-28.5
-33.8
BART10
BART13
BART-B
NM_017902 HIF1AN 139
132
-33.21,
-26.39
-35.5
-33.6
BART5
BART11-3p
BART-A
BART-B
NM_005933 MLL 139 -32.09 -33.3 BART5 BART-A
NM_002119 HLA-DOA 139 -29.87 -31.6 BART8* BART-B
NM_015717 CD207 136 -28.08 -30.7 BART20-3p BART-B
NM_022893 BCL11A 136 -23.04 -24.5 BART15 BART-A
B. EBF1 BART11-5p Target Site
EBF1
BART11-5p
5’ TAACTGTGCACCAGAACTGTCAGT 3’
     :|||| :           |   : |||||||  |
3’ GUUGAUCGCGUGGUUUGACAGACU 5’
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transfected/well in a ratio of 450 ng EBV-
miRNA expression construct or empty 
pcDNA3.1, 45 ng 3’UTR firefly luciferase report-
er construct and 5 ng pRL-TK for the renilla 
luciferase normalising construct.
When co-transfecting miRNA mimics and lucif-
erase reporters, cells were transfected using 
Lipofectamine 2000 (Invitrogen). Cells were 
transfected with 250 ng 3’UTR firefly luciferase 
reporter construct, 50 ng pRL-TK as a renilla 
luciferase normalising construct and 10 pmol 
of either BART11-5p miRNA mimic or negative 
siRNA control (Qiagen).
Real time reverse-transcription polymerase 
chain reaction
In order to confirm the expression of BART miR-
NAs from the EBV-miRNA expression con-
Table 3. The number of predicted targets for each EBV miRNA over the course of the bioinformatics 
analysis. For each EBV miRNA examined the number of potential targets predicted by the miRanda 
software from the RefSeq 3’UTR library and from a library of randomly generated sequences is indi-
cated. To obtain a measure of false positive target prediction the number obtained from the random 
library was subtracted from the number obtained from the RefSeq library. The number of potential tar-
gets from the RefSeq library exhibiting scores above those observed in the random library are shown. 
Potential targets identified by inputting the positive 3’UTRs identified by miRanda in a second program 
TargetScan. Final putative targets identified by both miRnada and TargetScan analyses are shown
miRNA Name
miRanda
TargetScan
RefSeq hits
Hits common to 
miRanda and 
TargetScanRefSeq hits Random hits
RefSeq minus 
Random hits
RefSeq hits above 
Random scores
BART1-5p 779 999 -220 7 92 4
BART1-3p 160 185 -25 4 67 2
BART2 242 148 94 13 446 9
BART3* 208 370 -162 3 66 2
BART3 134 148 -14 16 20 3
BART4 240 370 -130 5 99 4
BART5 603 703 -100 7 135 5
BART6-5p 353 185 168 5 58 2
BART6-3p 66 222 -156 8 33 3
BART7 211 333 -122 5 108 1
BART8 197 518 -321 5 17 0
BART8* 128 333 -205 6 131 3
BART9 135 222 -87 5 98 2
BART10 364 222 142 13 123 7
BART11-5p 232 407 -175 4 109 4
BART11-3p 113 74 39 41 38 2
BART12 1401 1368 33 7 177 5
BART13 380 296 84 6 68 2
BART14* 42 111 -69 2 24 0
BART14 519 407 112 5 188 4
BART15 501 259 242 18 82 4
BART16 366 370 -4 3 78 1
BART17-5p 281 222 59 5 157 4
BART17-3p 122 148 -26 8 157 2
BART18 89 74 15 4 124 2
BART19 629 259 370 11 330 8
BART20-5p 333 74 259 66 104 19
BART20-3p 232 0 232 48 178 30
*Potential BART-miRNA targets.
BART11-5p targets EBF1
215 Am J Blood Res 2013;3(3):210-224
structs, HEK 293T cells were transfected with 
EBV-miRNA expression constructs. Cells were 
seeded at 240,000 cells/well in 6 well plates 
and transfected with 2 µg EBV-miRNA expres-
sion construct. Transfected cells were pelleted 
48 hours post-transfection and RNA extracted 
using the mirVana miRNA Isolation Kit (Ambion). 
miRNA-cDNA was synthesised by polyadenylat-
ing RNA using the Poly(A) Polymerase Tailing Kit 
(Epicentre Biology). cDNA was synthesised via 
SuperScript III First Strand cDNA Synthesis Kit 
(Invitrogen) using the RTQ adapter primer (Table 
1C) to primer first strand synthesis, with final 
reaction diluted 1/10 with water. For miRNA 
real time PCR, reactions contained 0.2 µM miR-
NA-specific primer and RTQ-uniR2 primer, 0.1 
µM RTQ-probe, 1x GeneAmp II buffer, 1 U 
AmpliTaq Gold (Applied Biosystems), 0.2 µM 
dNTPs (Promega), 2.0 mM MgCl2, 1.0 M beta-
ine (Sigma) and 5 µL miRNA cDNA. Real time 
reverse-transcription PCR was performed in a 
Rotorgene RG-3000 thermal cycler (Corbett 
Research) using the following PCR program: 
95°C for 10 minutes followed by 45 cycles of 
95°C for 15 seconds and 60°C for 1 minute 
with fluorescence acquired at the end of the 
60°C incubation. Relative levels of expression 
were determined from the amplification curves 
generated during cycling using the Comparative 
Quantification analysis contained within the 
RotorGene 6 software package (Corbett 
Research). miRNA levels were calculated rela-
tive to a WIL EBV-transformed LCL and nor-
malised to U6 expression.
Luciferase assays
Transfected cells were lysed 48 hours after 
transfection using 100 µL 1X Passive Lysis 
Buffer (Promega). Luciferase assays were per-
formed using the Dual-Luciferase Reporter 
Assay System as per manufacturer’s instruc-
tions (Promega) and measured using the 
Synergy 4 Plate Reader (Bio Tek). Assays were 
performed in duplicate and performed with a 
minimum of three experimental replicates. 
Firefly luciferase activity was normalised to 
renilla luciferase activity and expressed rela-
tive to cells transfected with empty pcDNA3.1.
Results
EBV-miRNA target prediction
In order to predict potential targets of EBV-
miRNAs, an in silico analysis was performed, 
with a summary of results shown in Table 3. 
Initially the miRanda software package was 
used to determine predicted targets from the 
RefSeq 3’UTR. library (36985 sequences) using 
minimum score threshold of 130 and energy 
threshold (ΔG) of -16 kcal/mol. Here individual 
miRNAs exhibited a wide range in the number 
of predicated targets, ranging from 42 hits for 
BART14* to 1401 for BART12, with an average 
number of 316 targets per miRNA. This varia-
tion in the number of predicted targets per 
miRNA suggested biases within the miRanda 
algorithm towards certain sequences. To gain 
an understanding of this potential bias an anal-
ysis was performed using 1000 randomly gen-
erated DNA sequences with a G+C content dis-
tribution matched to that found in the Refseq 
3’UTR population. Analysis of this random set 
by miRanda using the same parameters as 
used for the RefSeq 3’UTR library generated a 
substantial number of hits (Table 1). 
Comparison of the number of hits for each EBV-
miRNA in both the RefSeq 3’UTR and random 
datasets revealed a highly significant correla-
tion (Pearson r=0.8158, p<0.0001), suggest-
ing a substantial component of the hits from 
the Refseq 3’UTR set were false positives. 
Interestingly 18 of the miRNAs had predicted 
proportionally fewer targets from the RefSeq 
3’UTR library than from the random sequences 
again suggesting a high level of false positive 
hits. To attempt to overcome these potential 
false positives an analysis was made excluding 
all RefSeq 3’UTR predicted targets with scores 
and ΔG values below that of the highest ranking 
hit from the random set for each miRNA. This 
resulted in a significant reduction in the pre-
dicted hits as shown in Table 3 with numbers 
ranging from 2 to 66 hits, with an average of 12 
hits per miRNA. 
To further filter putative targets and increase 
the rigour of our analysis, a second program, 
TargetScan, was used to analyse the RefSeq 
3’UTR library. This analysis produced 15 to 446 
(average 117) hits per miRNA as shown in Table 
3. In addition, the free energy binding of the 
EBV-miRNA against the target 3’UTR was 
assessed using RNAHybrid (Rehmsmeier et al., 
2004). Sequences that had been predicted to 
have miRNA target sites by both miRanda and 
TargetScan produced a final list of 154 poten-
tial targets with 0 to 30 hits per miRNA and an 
average of 5 hits per miRNA as shown in Table 
3. From these genes, ten potential targets for 
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Figure 2. Demonstration of specific miRNA expression from the EBV-miRNA expression constructs. Real time RT-
PCR following transfection of miRNA expression constructs. A: Expression levels of BART-A miRNAs. B: Expression of 
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laboratory analysis were selected on the basis 
of targeting by BART-encoded EBV-miRNAs and 
an association with EBV, B-cell lymphoma 
pathogenesis, B-cell differentiation, immuno-
modulation or apoptosis (Table 2). 
Validation of EBV-miRNA expression constructs
To enable examination of the effects of individ-
ual EBV-miRNAs a series of over-expression 
constructs was produced (Figure 1). To confirm 
specific EBV-miRNA expression quantitative 
real time RT-PCR analysis was performed on 
HEK293T cells transfected with the constructs 
(Figure 2A and 2B). This demonstrated that 
both pBART-A and pBART-B expressed mature 
BART miRNAs at levels comparable to those 
observed from an EBV-transformed LCL, with 
only very low levels of non-specific amplifica-
tion detected for some primers. For the con-
structs designed to produce restricted subsets 
of the BART-B EBV-miRNAs (Figure 2C) neither 
pBART-B1 nor pBART-B3 demonstrated expres-
sion of BART4, which is encoded within pBART-
A. pBART-B1 expressed both BART14-3p and 
BART13 at levels comparable to an EBV-
transformed LCL and did not express BART11-
5p. In contrast, pBART-B3 expressed BART11-
5p at comparable levels to an EBV-transformed 
LCL and did not express BART14-3p. In addi-
tion, expression levels from pBART-B1 and 
pBART-B3 were compared to the full pBART-B 
construct. This confirmed the restricted miRNA 
expression constructs to express miRNAs at 
comparable levels to pBART-B.
To confirm functionality of the EBV-miRNA over-
expression system the pBART-A construct was 
over-expression in combination with the EBV 
LMP1 gene 3’UTR fused to firefly luciferase. 
LMP1 mRNA is known to be silenced by EBV-
miRNAs within BART Cluster 1 [30], contained 
within pBART-A, and as such co-transfection 
should demonstrate silencing through reduced 
BART-B miRNAs. C: Expression levels of EBV-miRNAs from cells transfected with pBART-B, pBART-B1 or pBART-B3. 
Bars indicate mean and SEM of experimental duplicates. nd=none detected. miRNA expression levels were nor-
malised to U6 expression and reported relative to their expression in an EBV-transformed LCL.
Figure 3. Demonstration of functional miRNA expression from EBV-miRNA expression constructs. A: Firefly lumines-
cence of pGL3-LMP1-UTR reporter construct transfected into HEK293T cells in combination with pBART-A, pBART-B 
and empty pcDNA miRNA expression constructs. Bars indicate fold level of normalised luminescence relative to 
that of the pcDNA level for each cell line transfected. Bars indicate the mean of three experimental replicates, each 
consisting of two technical duplicates. B: Validation of BART11-5p positive control. Bars indicate the firefly lucifer-
ase activity of pGL3-rBART11 normalised to the Renilla luciferase activity when transfected with either pBART-A or 
pBART-B. Bars indicate the mean of four experimental replicates, each consisting of two technical duplicates. Error 
bars indicate SEM of the experimental replicates. p-value of one sample t-test against 1.0 to demonstrate signifi-
cance of change in luminescence with miRNA expression constructs indicated above bars.
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luminescence. Transfection was also per-
formed with the empty pcDNA3.1 verctor and 
pBART-B, and results normalized against 
Renilla luminescence from the constantly 
expressing pRL-TK construct and presented 
relative to the empty pcDNA3.1 vector. This 
revealed the pGL3-LMP1 positive control to 
exhibit a significant reduction in luciferase 
activity (39.3% ± 3.0%, p=0.0029) when co-
transfected with pBART-A with no evidence of 
silencing when co-transfected with pBART-B 
(Figure 3A). 
An additional positive control was developed 
which is specifically targeted by the BART11 
miRNAs, termed pGL3-rBART11. pGL3-rBART- 
Figure 4. Validation of the bioinformaticsally predicted (A) BART-A targets and (B) BART-B targets. Activity of firefly 
luciferase reporter constructs was normalised against the expression of Renilla luciferase and expression was re-
ported relative to luciferase activity in cells not overexpressing BART miRNAs which was arbitrarily defined as 1.0 
and is indicated by the dashed lines. Data presented is mean ± SEM, n=4 except for luciferase assays of BCL11A 
and CD207 which were performed in triplicate. All experiments were performed with technical duplicates. Signifi-
cance of fold changes with miRNA expression determined by one-sample T-tests with result summaries indicated 
above each column. ns=not significant. (*) p<0.05. (***) p<0.001.
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Experimental validation of predicted target 
sites
To determine the functionality of the putative 
BART miRNA targets identified above luciferase 
reporter assays were performed (Figure 4). For 
the six selected genes predicted to be targeted 
by miRNAs contained within the BART-A cluster 
no significant alteration in expression was 
11 was co-transfected with pBART-A and 
pBART-B in order to validate it as a positive con-
trol (Figure 3B). There was no evidence of 
silencing upon co-transfection with pBART-A 
but there was a significant decrease 25.8% ± 
5.8%, p=0.0209) in luciferase activity upon co-
transfection with pBART-B. These findings pro-
vide validation of the positive control 
pGL3-rBART11.
Figure 5. Experimental verification of predicted miR-BART11-5p silencing via predicted EBF1-3’UTR site. A: Bars 
indicate the firefly luciferase activity of truncated, site-specific EBF1-3’UTR luciferase reporter construct normalised 
to the Renilla luciferase activity when transfected with either pBART-A or pBART-B miRNA expression constructs 
relative to cells transfected with an empty pcDNA miRNA expression construct. Bars indicate the mean of five ex-
perimental replicates, each consisting of two technical duplicates. B: Bars indicate the firefly luciferase activity of 
truncated, site-specific EBF1-3’UTR or BART11-specific positive control luciferase reporter constructs normalised 
to the Renilla luciferase activity when transfected with miRNA expression constructs expressing restricted subsets 
of pBART-B miRNAs relative to cells transfected with an empty pcDNA miRNA expression construct. Bars indicate 
the mean of three experimental replicates, each consisting of two technical duplicates. C: Bars indicate the firefly 
luciferase activity of luciferase reporter constructs normalised to the Renilla luciferase activity when transfected 
with 10 pmol of synthetic BART11-5p mimic relative to cells transfected with a negative control siRNA. Bars indicate 
the mean of two experimental replicates for pGL3-EBF1 and pGL3-EBF1-site and three experimental replicates for 
pGL3-rBART11, each consisting of two technical duplicates. Error bars indicate SEM of the experimental replicates. 
Results of one sample t-test against 1.0 are indicated above bars, ns=not significant. (*) p<0.05. (***) p<0.001.
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significant reduction in luciferase levels 
observed when co-transfected with pBART-A. 
When co-transfected with pBART-B, the lucifer-
ase expression of pGL3-EBF1-site was signifi-
cantly reduced by 43.9% ± 12.7% (SEM) 
(p=0.0258) (Figure 5A). This strongly support 
the functionality of the predicted BART11-5p 
site at position 2137 of the EBF1-3’UTR.
In order to confirm that miR-BART11-5p was 
responsible for the silencing of pGL3-EBF1-site, 
additional luciferase assays were performed 
with co-transfection of pBART-B1 and pBART-
B3, miRNA expression constructs expressing 
reduced subsets of BART miRNAs. Here no 
silencing of luciferase expression was observed 
with co-transfection of pBART-B1, however sig-
nificant levels of silencing were observed upon 
co-transfection with both pBART-B3 and 
pBART-B3* (Figure 5B). pBART-B3 repressed 
luciferase expression by 50.6% ± 11.2% 
(p=0.0458) compared to co-transfection of 
pGL3-EBF1-site with an empty miRNA expres-
sion construct. pBART-B3* repressed lucifer-
ase expression by 37.2% ± 3.0% (p=0.0063). In 
addition, an unpaired t test was performed to 
compare the level of silencing between co-
transfections with pBART-B3 and pBART-B3* 
however there was no significant difference in 
silencing between these two constructs. These 
levels of silencing were comparable to that of 
the positive control pGL3-rBART11 which dem-
onstrated a 47.2% ± 5.2% (p=0.0120) and a 
39.6% ± 8.6% (p=0.0439) level of silencing 
when co-transfected with pBART-B3 and 
pBART-B3* respectively. As both pBART-B3 
and pBART-B3* both express BART11-5p and 
there was no statistical difference in the levels 
of silencing between the two miRNA expression 
constructs, these findings provide further sup-
port that BART11-5p does repress EBF1 at the 
predicted site.
In order to test the individual effect of BART11-
5p on the predicted target site within the EBF1-
3’UTR, luciferase assays were performed using 
a synthetic miRNA mimic of BART11-5p. The 
miRNA mimic was first validated against pGL3-
rBART11 and significant silencing (55.1% ± 
2.1%, p=0.0014) of luciferase expression was 
observed (Figure 5C). Luciferase assays were 
then performed with the site specific EBF1 
reporter (pGL3-EBF1-site), demonstrating a 
statistically significant degree of silencing 
(32.8% ± 6.4%, p=0.0361) of pGL3-EBF1-site 
observed when the pBART-A construct was co-
transfected with the reporter constructs. 
Interestingly when the BART-A target reporter 
constructs were co-transfected with pBART-B a 
highly significant, reproducible reduction 
(23.2% ± 1.7%, p=0.008) in luciferase activity 
was observed for the BCL2L11 construct. In 
addition, pGL3-MLL exhibited a large yet statis-
tically insignificant reduction in luciferase activ-
ity (30.3% ± 11.4%, p=0.0763), when BART-B 
miRNAs were overexpressed. For the five 
selected genes predicted to be targeted by 
BART-B miRNAs, the EBF1 construct was the 
only target that exhibited a significant reduction 
in luciferase activity (33.2% ± 7.2%, p=0.0192) 
due to expression of BART-B miRNAs. Again 
unexpectedly a third significant target was iden-
tified when the predicted BART-B targets were 
assayed with the expression of BART-A miR-
NAs. The HLA-DOA construct exhibited a signifi-
cant reduction in luciferase activity (21.49% ± 
6.7%, p=0.0485). 
Two of the three positive results were not pre-
dicted by the bioinformatics analysis. While 
EBF1 was predicted to be targeted by a miRNA 
within the BART-B cluster, neither HLA-DOA nor 
BCL2L11 were down regulated by their predict-
ed BART miRNA clusters. To determine the pre-
viously undetermined sites underlying this 
down regulation the bioinformatics data was 
reanalysed for these two gene’s 3’UTRs. This 
revealed a second potential target site within 
the BCL2L11 3’UTR for BART14-3p, a miRNA 
within the BART-B cluster. This target site had 
been excluded during filtering of the results 
using random 3’UTRs. No secondary target site 
was identified for the HLA-DOA 3’UTR within the 
miRanda bioinformatics scan and the miRNAs 
targeting these genes and potential target sites 
remain unknown.
Experimental verification of predicted miR-
BART11-5p silencing of EBF1
As EBF1 was the highest bioinformatically 
ranked target to exhibit silencing by the predict-
ed BART expression construct, this gene was 
chosen for further study. The predicted target 
site within EBF1 was experimentally verified via 
luciferase silencing assays using the site-spe-
cific luciferase reporter pGL3-EBF1-site. This 
construct contained a 151 bp fragment of the 
EBF1-3’UTR containing the bioinformatically 
predicted target site. As expected, there was no 
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activity in B-cells [38]. This suggests a mecha-
nism ensuring B-cell specificity of EBV latency 
expression and highlights another possible 
function of EBF1 targeting by EBV-miRNAs, 
namely to regulate the expression of EBV laten-
cy genes.
Our previous data has confirmed that BART11-
5p is expressed in a range of EBV-associated 
B-cell lymphoma types with a variety of latency 
profiles including PTLD, DLBCL and BL [21]. 
BART11-5p is also highly expressed in lympho-
mas of non-B-cell origin [39], suggesting a con-
tributing to the pathogenesis of these tumors. 
In contrast, the expression of BART11-5p within 
the EBV-associated malignancy nasopharyn-
geal carcinoma (NPC) is barely above back-
ground levels [40]. Although BART miRNAs are 
expressed from the same promoter, the levels 
of individual miRNAs differ widely from one 
another [24]. Interestingly, it has been asserted 
that the expression of miRNA targets protects 
miRNAs from degradation, resulting in an 
increase in the levels of the miRNA [41]. Thus 
one possible explanation for the difference in 
the expression of BART11-5p between lym-
phoid and epithelial malignancies is that NPC 
contains few miRNA targets for BART11-5p. In 
support of this notion, EBF1 is expressed in 
both normal and malignant B-cells, whereas 
the expression of EBF1 in NPC has not been 
detected [31, 42].
Our study provides evidence of a miRNA target 
site within the EBF1-3’UTR, 2137 bp after the 
stop codon, targeted by the EBV-miRNA 
BART11-5p. This target site (Table 2B) shows a 
high degree of complementarity to BART11-5p 
but does not exhibit perfect complementarity 
within the seed region (5’ nucleotides 2-7). 
While the perfect complementarity of the seed 
region has long been considered one of the 
defining motifs of potential miRNA target sites, 
extensive binding of the 3’ region of the miRNA, 
in particular nucleotides 12-16, can compen-
sate for imperfect complementarity of the seed 
region and a recent study has demonstrated 
miRNAs which bind to sites with a “centred 
site” motif [43]. Our study did not explore the 
specific binding characteristics of BART11-5p 
to its predicted target site but given the degree 
of pairing, it is conceivable that the high degree 
of complementarity within the 3’ region com-
pensates for the imperfect complementarity of 
the seed region.
by the BART11-5p mimic (Figure 5C). In con-
trast, the whole EBF1-3’UTR shows no evidence 
of silencing of luciferase activity by BART11-5p 
(Figure 5C).
Discussion
In this study, EBF1 was identified as a novel tar-
get of EBV-miRNA BART11-5p. Following bioin-
formatics analysis (using three separate miRNA 
prediction tools), we performed luciferase 
reporter assays with a series of BART-
constructs, and confirmed inhibition of the 
EBF1-3’UTR and identified the target site as 
2137 bp after the stop codon. Results were 
confirmed following transfection of a BART11-
5p mimic which was able to inhibit the target 
site. Our findings highlight a potential role of 
BART-miRNAs in the regulation of B-cell 
differentiation. 
EBF1 is an important B-cell transcription factor 
that is crucial for germinal centre formation 
[31, 32]. Recent studies have demonstrated 
that EBF1 is expressed during all stages of 
B-cell differentiation with the exception of plas-
ma cells. In its absence fully functioning, 
mature B-cells are unable to develop [33]. It 
targets a number of B-cell specific genes includ-
ing the B-cell developmental regulator Pax5 
(which is necessary for the maintenance of the 
B-cell phenotype), the B-cell receptor (BCR) and 
Bim [34]. In addition, the activity of EBF1 is reg-
ulated by CD40, a crucial B-cell signalling 
receptor that is involved in germinal centre dif-
ferentiation [35]. 
EBV-driven transformation of B-cells drives an 
atypical germinal centre reaction [3], indicating 
that the modulation of EBF1 expression by EBV 
may play a role in this process. This is support-
ed by the interaction of EBF1 with the latency III 
viral gene EBV nuclear antigen-2 (EBNA2), 
which has been found to be enriched at EBF1 
transcription sites, suggesting that EBNA2 may 
associate with EBF1 in order to co-target EBF1-
regulated genes [36]. Furthermore Latent 
Membrane Protein-2A (LMP2A) alters the 
expression of EBF1 through the Notch signal-
ling pathway [37]. Additionally, binding sites for 
Pax5, one of the primary and most well-charac-
terised targets of EBF1, have been identified in 
the Wp sequence, one of the primary promot-
ers governing EBV latency gene expression. 
Mutation of these binding sites prevents viral 
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stein-Barr virus microRNAs are evolutionarily 
conserved and differentially expressed. PLoS 
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Epstein-Barr virus microRNA genes from naso-
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3333-3341.
It has been demonstrated that several EBV-
miRNAs share seed sequences with human 
miRNAs, possibly in order to regulate existing 
miRNA regulatory networks [44]. Unfortunately, 
little is known about miR-1324 and no targets 
have been identified. miR-1324 was isolated 
from neuroblastoma samples and, of note 
EBF1 is not only responsible for regulating 
B-cell differentiation but also for regulating 
neuronal differentiation [45].
In summary, we identify EBF1 as a novel target 
of EBV-miRNA BART11-5p. Our findings high-
light a potential role of BART-miRNAs in the 
regulation of B-cell differentiation. Further 
investigation into the targeting of EBF1 by EBV-
miRNAs during B-cell differentiation and lym-
phomagenesis is warranted.
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